Aller au contenu principal

 Articles scientifiques

Correction to: Combined quality and dose-volume histograms for assessing the predictive value of <sup>99m</sup>Tc-MAA SPECT/CT simulation for personalizing radioembolization treatment in liver metastatic colorectal cancer.

Auteurs : Levillain H, Burghelea M, Derijckere ID, Guiot T, Gulyban A, Vanderlinden B, Vouche M, Flamen P, Reynaert N
Année : 2021
Journal : EJNMMI Phys
Volume : 8
Pages : 9

Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III clinical trial.

Auteurs : Venet D, Rediti M, Maetens M, Fumagalli D, Brown DN, Majjaj S, Salgado R, Pusztai L, Harbeck N, El-Abed S, Wang Y, Saura C, Gomez H, Semiglazov V, de Azambuja E, Huober J, Nuciforo P, Di Cosimo S, Piccart-Gebhart M, Loi S, Rothé F, Sotiriou C
Année : 2021
Journal : Clin Cancer Res

Combined Metabolically Active Tumor Volume and Early Metabolic Response Improve Outcome Prediction in Metastatic Colorectal Cancer.

Auteurs : Woff E, Salvatore L, Marmorino F, Genovesi D, Critchi G, Guiot T, Ameye L, Sclafani F, Hendlisz A, Flamen P
Année : 2021
Journal : J Nucl Med

Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial.

Auteurs : Vandeputte C, Bregni G, Gkolfakis P, Guiot T, Pretta A, Kehagias P, Senti C, Reina EA, Van Bogaert C, Deleporte A, Geboes K, Delaunoit T, Demolin G, Peeters M, DHondt L, Janssens J, Carrasco J, Holbrechts S, Goeminne JC, Vergauwe P, Van Laethem JL, Flamen P, Hendlisz A, Sclafani F
Année : 2021
Journal : Clin Colorectal Cancer

Circulating Tumor DNA to Interrogate the Safety of Letrozole-Associated Controlled Ovarian Stimulation for Fertility Preservation in Breast Cancer Patients.

Auteurs : Rothé F, Lambertini M, Goldrat O, Maetens M, Bareche Y, Blanc J, Rouas G, Larsimont D, Sotiriou C, Ignatiadis M, Demeestere I
Année : 2021
Journal : Front Oncol
Volume : 11
Pages : 686625

Fat density is a novel prognostic marker in patients with esophageal cancer.

Auteurs : Anciaux M, Van Gossum A, Wenglinski C, Ameye L, Guiot T, Flamen P, Demetter P, Deleporte A, Sclafani F, Donckier V, Hendlisz A, Vandeputte C
Année : 2020
Journal : Clin Nutr ESPEN
Volume : 39
Pages : 124-130

Prognostic Value of the Pace of Tumor Progression as Assessed by Serial 18 F-FDG PET/CT Scan and Liquid Biopsy in Refractory Colorectal Cancer: The CORIOLAN Trial.

Auteurs : Camera S, Akin Telli T, Woff E, Vandeputte C, Kehagias P, Guiot T, Critchi G, Wissam Y, Bregni G, Trevisi E, Pretta A, Senti C, Leduc S, Gkolfakis P, Hoerner F, Rothé F, Sclafani F, Flamen P, Deleporte A, Hendlisz A
Année : 2020
Journal : Cancers (Basel)
Volume : 12

Phylogenetic reconstruction of breast cancer reveals two routes of metastatic dissemination associated with distinct clinical outcome.

Auteurs : Venet D, Fimereli D, Rothé F, Boeckx B, Maetens M, Majjaj S, Rouas G, Capra M, Bonizzi G, Contaldo F, Galant C, Piccart-Gebhart M, Pruneri G, Larsimont D, Lambrechts D, Desmedt C, Sotiriou C
Année : 2020
Journal : EBioMedicine
Volume : 56
Pages : 102793

Digital analysis of distant and cancer-associated mammary adipocytes.

Auteurs : Isnaldi E, Richard F, De Schepper M, Vincent D, Leduc S, Maetens M, Geukens T, Floris G, Rouas G, Cardoso F, Sotiriou C, Zoppoli G, Larsimont D, Biganzoli E, Desmedt C
Année : 2020
Journal : Breast
Volume : 54
Pages : 179-186

Combined quality and dose-volume histograms for assessing the predictive value of <sup>99m</sup>Tc-MAA SPECT/CT simulation for personalizing radioembolization treatment in liver metastatic colorectal cancer.

Auteurs : Levillain H, Burghelea M, Derijckere ID, Guiot T, Gulyban A, Vanderlinden B, Vouche M, Flamen P, Reynaert N
Année : 2020
Journal : EJNMMI Phys
Volume : 7
Pages : 75

Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells.

Auteurs : Gómez-Aleza C, Nguyen B, Yoldi G, Ciscar M, Barranco A, Hernández-Jiménez E, Maetens M, Salgado R, Zafeiroglou M, Pellegrini P, Venet D, Garaud S, Trinidad EM, Benítez S, Vuylsteke P, Polastro L, Wildiers H, Simon P, Lindeman G, Larsimont D, Van den Eynden G, Velghe C, Rothé F, Willard-Gallo K, Michiels S, Muñoz P, Walzer T, Planelles L, Penninger J, Azim HA Jr, Loi S, Piccart-Gebhart M, Sotiriou C, González-Suárez E
Année : 2020
Journal : Nat Commun
Volume : 11
Pages : 6335

Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study.

Auteurs : Levillain H, Duran Derijckere I, Ameye L, Guiot T, Braat A, Meyer C, Vanderlinden B, Reynaert N, Hendlisz A, Lam M, Deroose CM, Ahmadzadehfar H, Flamen P
Année : 2019
Journal : Eur J Nucl Med Mol Imaging
Volume : 46
Pages : 2270-2279

CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial.

Auteurs : Rothé F, Maetens M, Rouas G, Paesmans M, Van den Eynde M, Van Laethem JL, Vergauwe P, Deboever G, Bareche Y, Vandeputte C, Ignatiadis M, Hendlisz A
Année : 2019
Journal : BMC Cancer
Volume : 19
Pages : 304

Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial.

Auteurs : Rothé F, Silva MJ, Venet D, Campbell C, Bradburry I, Rouas G, de Azambuja E, Maetens M, Fumagalli D, Rodrik-Outmezguine V, Di Cosimo S, Rosa D, Chia S, Wardley A, Ueno T, Janni W, Huober J, Baselga J, Piccart-Gebhart M, Loi S, Sotiriou C, Dawson SJ, Ignatiadis M
Année : 2019
Journal : Clin Cancer Res
Volume : 25
Pages : 3581-3588

Combining 18F-FDG PET/CT-Based Metabolically Active Tumor Volume and Circulating Cell-Free DNA Significantly Improves Outcome Prediction in Chemorefractory Metastatic Colorectal Cancer.

Auteurs : Woff E, Kehagias P, Vandeputte C, Ameye L, Guiot T, Paesmans M, Hendlisz A, Flamen P
Année : 2019
Journal : J Nucl Med
Volume : 60
Pages : 1366-1372

Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials.

Auteurs : Charette N, Vandeputte C, Ameye L, Bogaert CV, Krygier J, Guiot T, Deleporte A, Delaunoit T, Geboes K, Van Laethem JL, Peeters M, Demolin G, Holbrechts S, Flamen P, Paesmans M, Hendlisz A
Année : 2019
Journal : BMC Cancer
Volume : 19
Pages : 134

Validation of Metabolically Active Tumor Volume and Total Lesion Glycolysis as 18F-FDG PET/CT–derived Prognostic Biomarkers in Chemorefractory Metastatic Colorectal Cancer

Auteurs : Woff E, Hendlisz A, Ameye L, Garcia C, Kamoun T, Guiot T, Paesmans M, Flamen P
Année : 2019
Journal : J Nucl Med
Volume : 60
Pages : 178-184

Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy.

Auteurs : Ignatiadis M, Van den Eynden G, Roberto S, Fornili M, Bareche Y, Desmedt C, Rothé F, Maetens M, Venet D, Holgado E, McNally V, Kiermaier A, Savage HM, Wilson TR, Cortes J, Schneeweiss A, Willard-Gallo K, Biganzoli E, Sotiriou C
Année : 2019
Journal : J Natl Cancer Inst
Volume : 111
Pages : 69-77

A dosimetry procedure for organs-at-risk in <sup>177</sup>Lu peptide receptor radionuclide therapy of patients with neuroendocrine tumours.

Auteurs : Marin G, Vanderlinden B, Karfis I, Guiot T, Wimana Z, Reynaert N, Vandenberghe S, Flamen P
Année : 2018
Journal : Phys Med
Volume : 56
Pages : 41-49

90Y-PET/CT-based dosimetry after selective internal radiation therapy predicts outcome in patients with liver metastases from colorectal cancer.

Auteurs : Levillain H, Duran Derijckere I, Marin G, Guiot T, Vouche M, Reynaert N, Hendlisz A, Vanderlinden B, Flamen P
Année : 2018
Journal : EJNMMI Res
Volume : 8
Pages : 60